Methylphenidate
| MPH | |
|---|---|
| Salts [] | |
|---|---|
| Methylphenidate hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Rotamer [] | |
|---|---|
| Conformer structure via 3Dmol.js |
| Physical properties [] | |
|---|---|
| Molecular mass | 233.31 g/mol [1] |
| Appearance | Crystals from ethanol (aqueous) [1] |
| Melting point | 74-75 °C [1] |
| Boiling point | BP: 135 to 137 °C at 0.6 mm Hg [1] |
| Decomposition | When heated to decomposition it emits toxic fumes of nitroxides. [1] |
| Solubility | 1255mg/L [1] |
| Predicted LogP | 0.2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C14H19NO2 |
| IUPAC name | methyl 2-phenyl-2-piperidin-2-ylacetate |
| SMILES | COC(=O)C(C1CCCCN1)C2=CC=CC=C2 |
| InChI | InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3 |
| InChIKey | DUGOZIWVEXMGBE-UHFFFAOYSA-N |
| CAS number | 113-45-1 |
| UNII | 207ZZ9QZ49 |
| PubChem CID | 4158 |
| Pharmacokinetics[] | |
|---|---|
| Onset | ~20–60 minutes, depending on formulation |
| Elimination half-life | 2—3 hours |
| Duration of action | Immediate Release dosing: 3–4 hours, Extended Release dosing: 8–12 hours |
| Metabolism | Liver (80%) mostly CES1-mediated |
| Excretion | Urine (90%) |
| Routes of administration | Medical: Oral, transdermal, Recreational: Oral, insufflation, sublingual, rectal, intravenous |
| Dependence liability | Physical: None, Psychological: Moderate[3] |
| Addiction liability | Moderate |
| Toxicity [] | |
|---|---|
| LD50 | Mice: - oral: 190 mg/kg Mouse: - oral: 190 mg/kg /Methylphenidate - ip: 32 mg/kg - sc: 218 mg/kg - iv: 41 mg/kg Rat: - ip: 430 mg/kg [1] |
| Dosing[] |
|---|
| Buccal [] | |
|---|---|
| Light | ≤ 31.6 mg(12x - 33.3%) |
| Common | 31.6 - 40 mg(8x - 22.2%) |
| Strong | 40 - 60 mg(10x - 27.8%) |
| Heavy | 60 - 85 mg(2x - 5.6%) |
| Extreme | 85 mg +(4x - 11.1%) |
| Insufflated [] | |
|---|---|
| Light | ≤ 32.7 mg(76x - 30.4%) |
| Common | 32.7 - 40 mg(64x - 25.6%) |
| Strong | 40 - 60 mg(49x - 19.6%) |
| Heavy | 60 - 116.3 mg(35x - 14.0%) |
| Extreme | 116.3 mg +(26x - 10.4%) |
| Intravenous [] | |
|---|---|
| Light | ≤ 8.8 mg(1x - 25.0%) |
| Common | 8.8 - 10 mg(2x - 50.0%) |
| Strong | 10 - 15 mg |
| Heavy | 15 - 24 mg |
| Extreme | 24 mg +(1x - 25.0%) |
| Subcutaneous [] | |
|---|---|
| Light | ≤ 40.9 mg(2x - 66.7%) |
| Common | 40.9 mg |
| Strong | 40 - 50 mg |
| Heavy | 50 - 56 mg |
| Extreme | 56 mg +(1x - 33.3%) |
| Sublingual [] | |
|---|---|
| Light | ≤ 34.5 mg(74x - 27.2%) |
| Common | 34.5 - 40 mg(80x - 29.4%) |
| Strong | 40 - 60 mg(53x - 19.5%) |
| Heavy | 60 - 98 mg(37x - 13.6%) |
| Extreme | 98 mg +(28x - 10.3%) |
| Oral [] | |
|---|---|
| Light | ≤ 24.8 mg(122x - 43.1%) |
| Common | 24.8 - 36 mg(37x - 13.1%) |
| Strong | 36 - 72 mg(57x - 20.1%) |
| Heavy | 72 - 108 mg(40x - 14.1%) |
| Extreme | 108 mg +(27x - 9.5%) |
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki) We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Methylphenidate (also known as Methylphenidan, Phenidylate, Calocain, Plimasine, Daytrana, Methyl phenidylacetate, Metilfenidato, Methylphenidatum, 4311/B Ciba or Methyl phenidate) is a stimulant substance of the phenidate class.
Chemistry
Salts []
Stereochemistry []
Methylphenidate is a racemic mixture of the diastereomers (optical activity ( + / - )).
Druglikeness
Lipinski's rule of five
Methylphenidate matches Lipinski's rule of five.Reagents
There are currently 8 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | light orange | |
| Mandelin | short reddish | |
| Liebermann | yellow - orange | |
| Froehde | no color change -> Tan | |
| Simon's | pale violet | |
| Hofmann | no color change | |
| Scott | no color change | |
| Zimmermann | slow purple |
Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- psychostimulants, agents used for adhd and nootropics (N06B)
- centrally acting sympathomimetics (N06BA)
- (N06BA04)
- methylphenidate (N06BA04)
MeSH Classification
Mechanism of action []
While its exact mechanism is unclear, methylphenidate (MPH) has been shown to act as a norepinephrine and dopamine reuptake inhibitor (NDRI), thereby increasing the presence of these neurotransmitters in the extraneuronal space and prolonging their action. There is a dose-related effect of psychostimulants on receptor stimulation, where higher doses are shown to increase norepinephrine (NE) and dopamine (DA) efflux throughout the brain which can result in impaired cognition and locomotor-activating effects. In contrast, low doses are found to selectively activate NE and DE neurotransmission within the prefrontal cortex which is an area of the brain thought to play a prominent role in ADHD pathophysiology, thereby improving clinical efficacy and preventing side effects. The lower doses used to treat ADHD are not associated with the locomotor-activating effects associated with higher doses and instead reduce movement, impulsivity, and increase cognitive function including sustained attention and working memory. Methylphenidate's beneficial effects in sustaining attention have also been shown to be mediated by alpha-1 adrenergic receptor activity. Clinical findings have shown that children with ADHD have an abnormality in the dopamine transporter gene (DAT1), the D4 receptor gene (DRD-4), and/or the D2 receptor gene that may be at least partly overcome by the dopaminergic effects of methylphenidate, suggesting a possible mode of action. [1]
Interactions []
Medical side effects []
311 side effects listed on drug labels in SIDER 4.1 (methylphenidate).
- Nervous system disorder
- Mental disorder
- Gastrointestinal disorder
- Decreased appetite
- Anorexia
- Appetite absent
- Headache
- Malnutrition
- Dry mouth
- Mediastinal disorder
- Dyspepsia
- Nausea
- Abdominal pain upper
- Stomach ache
- Anxiety
- Hyperhidrosis
- Sweating
- Toothache
- Sleep disorder
- Insomnia
- Blood pressure fluctuation
- Lethargy
- Asthenia
- Fatigue
- Initial insomnia
- Infestation
- Laryngeal pain
- Nervousness
- Feeling jittery
- Palpitations
- Agitation
- Hyperkinesia
- Nasopharyngitis
- Vomiting
- Tremor
- Diarrhoea
- Infection
- Body temperature increased
- Hypertension
- Upper respiratory tract infection
- Excoriation
- Motion sickness
- Application site reaction
- Eye pain
- Cough
- Cough increased
- Dizziness
- Syncope
- Muscle tightness
- Thirst
- Bruxism
- Connective tissue disorder
- Libido decreased
- Disturbance in sexual arousal
- Vertigo
- Vision blurred
- Constipation
- Irritability
- Affect lability
- Mood swings
- Oropharyngeal pain
- Throat sore
- Sinusitis
- Panic attack
- Abdominal discomfort
- Upset stomach
- Menopausal symptoms
- Hot flush
- Confusional state
- Feeling abnormal
- Malaise
- Dyspnoea
- Pain
- Paraesthesia
- Tension headache
- Tension
- Muscle spasms
- Cramp muscle
- Cramps of lower extremities
- Alanine aminotransferase increased
- Erectile dysfunction
- Somnolence
- Drowsiness
- Depression
- Abdominal pain
- Gastrointestinal pain
- Aggression
- Alopecia
- Anaphylactic shock
- Anaemia
- Aplastic anaemia
- Angina pectoris
- Angioedema
- Arrhythmia
- Arthralgia
- Musculoskeletal discomfort
- Myalgia
- Bone disorder
- Breast disorder
- Cerebral arteritis
- Chest pain
- Chest discomfort
- Chest pain exertional
- Contusion
- Sudden death
- Dermatitis
- Rash
- Dermatitis exfoliative
- Diplopia
- Dyskinesia
- Eczema
- Oedema
- Grand mal convulsion
- Erythema multiforme
- Stevens-Johnson syndrome
- Eruption
- Eye disorder
- Hallucination
- Cardiac arrest
- Cardiac disorder
- Haemorrhage
- Haemoglobin
- Coma hepatic
- Hypersensitivity
- Hypoglycaemia
- Immune system disorder
- Inflammation
- Leukopenia
- Mydriasis
- Neuroleptic malignant syndrome
- Obsessive-compulsive disorder
- Pancreatitis
- Pancytopenia
- Priapism
- Psychotic disorder
- Convulsion
- Completed suicide
- Suicide attempt
- Swelling
- Tachycardia
- Supraventricular tachycardia
- Thrombocytopenia
- Tourette's disorder
- Ulcer
- Erythema
- Urticaria
- Angiopathy
- Weight increased
- Weight decreased
- Sudden cardiac death
- Hepatic function abnormal
- Migraine
- Ventricular extrasystoles
- Growth retardation
- Blood alkaline phosphatase increased
- Accommodation disorder
- Dermatitis contact
- Skin hyperpigmentation
- Leukoderma
- Skin disorder
- Scab
- Drug eruption
- Muscle twitching
- Disorientation
- Abnormal behaviour
- Hallucination, auditory
- Hallucination, visual
- Discomfort
- Therapeutic response decreased
- Hepatic enzyme increased
- Skin exfoliation
- Peripheral coldness
- Blood bilirubin increased
- Induration
- Papule
- Mania
- Extrasystoles
- Depressed mood
- Feeling sad
- Feeling hot
- Platelet count decreased
- Hyperpyrexia
- Suicidal ideation
- Bradycardia
- Blood pressure increased
- Drug effect decreased
- Visual impairment
- Abnormal vision
- Auricular swelling
- Reversible ischaemic neurological deficit
- White blood cell count abnormal
- Drug interaction
- Thrombocytopenic purpura
- Vasculitis necrotising
- Suicidal behaviour
- Logorrhoea
- Cerebrovascular disorder
- Cerebrovascular accident
- Vasculitis
- Hallucination, tactile
- Choreoathetosis
- Cerebral haemorrhage
- Abscess
- Albuminuria
- Anger
- Asthma
- Back pain
- Bronchitis
- Neck pain
- Coma
- Conjunctivitis
- Dehydration
- Delirium
- Dental caries
- Depersonalisation
- Diabetes mellitus
- Dysmenorrhoea
- Ear disorder
- Ear pain
- Ecchymosis
- Epistaxis
- Flushing
- Gastritis
- Gastroenteritis
- Glaucoma
- Gynaecomastia
- Cardiac murmur
- Blood disorder
- Haematuria
- Haemorrhoids
- Hernia
- Herpes virus infection
- Hiccups
- Hostility
- Influenza
- Laryngitis
- Fungal infection
- Myocardial infarction
- Acute coronary syndrome
- Nail disorder
- Nasal congestion
- Nasal polyps
- Neoplasm
- Neurosis
- Obstruction
- Otitis media
- Pain in extremity
- Personality disorder
- Petechiae
- Pharyngitis
- Pneumonia
- Pruritus
- Psoriasis
- Anorectal disorder
- Rhinitis
- Serum sickness
- Speech disorder
- Stereotypy
- Shock
- Loss of consciousness
- Attention deficit/hyperactivity disorder
- Urethral disorder
- Urinary tract disorder
- Peripheral vascular disorder
- Chills
- Skin odour abnormal
- Apathy
- Flat affect
- Rash pustular
- Benign neoplasm
- Corneal lesion
- Injury
- Liver function test abnormal
- Adverse reaction
- Hyperreflexia
- Skin discolouration
- Skin irritation
- Photosensitivity reaction
- Photosensitivity
- Rash macular
- Ill-defined disorder
- Weight gain poor
- Increased appetite
- Thinking abnormal
- Mental disability
- Abnormal dreams
- Hypervigilance
- Euphoric mood
- Gastrointestinal obstruction
- Lip swelling
- Hypomania
- Oropharyngeal discomfort
- Hepatobiliary disease
- Dry eye
- Cardiac death
- Akathisia
- Crying
- Tearfulness
- Ligament sprain
- Lymphadenopathy
- Paralysis
- Ear infection
- Poisoning
- Tic
- Vocal tic
- Local reaction
- Libido disorder
- Sympathomimetic effect
- Sensitisation
- Drug dependence
- Overdose
Indications
- Attention deficit disorder
- Attention deficit/hyperactivity disorder
- Brain injury
- Cardiovascular disorder
- Cerebral dysfunction
- Daytime sleepiness
- Distractibility
- Drowsiness
- Electroencephalogram abnormal
- Forgetfulness
- Heart malformation
- Hyperkinesia
- Learning disability
- Mental disorder
- Minimal brain dysfunction
- Mood swings
- Narcolepsy
- Psychotic disorder
- Sudden death
- Ventricular arrhythmia
Subjective effects []
| 0xea / Methylphenidate [] | |
|---|---|
Routes:
| |
| a1ko / Methylphenidate [] | |
|---|---|
Routes:
| |
| alina / Methylphenidate [] | |
|---|---|
Routes:
| |
| bonzi / Methylphenidate [] | |
|---|---|
Routes:
| |
| emily / Methylphenidate [] | |
|---|---|
Routes:
| |
| magnus / Methylphenidate [] | |
|---|---|
Routes:
| |
| Mere / Methylphenidate [] | |
|---|---|
| michalina / Methylphenidate [] | |
|---|---|
| nervewing / Methylphenidate [] | |
|---|---|
| ninerik / Methylphenidate [] | |
|---|---|
Routes:
| |
| Pilz / Methylphenidate [] | |
|---|---|
Routes:
| |
| vivi / Methylphenidate [] | |
|---|---|
Routes:
| |
Experience reports
- "I Have Tried Every Single Drug and Steroid" by Hangeth_Thy_Dong (51 upvotes)
- "Weed became my nicotine" by stjakey (30 upvotes)
- "Every Drug I've taken so far (AMA)" by Used-Philosopher-408 (26 upvotes)
- "Meth psychosis trip report" by 0bscurious (25 upvotes)
- "Disrespect psychs and they'll show you" by Mimiriam (23 upvotes)
- "9g Lemon-Tekked Golden Teachers" by SibylLuminary (14 upvotes)
- "First time salvia" by dexamfetamin (13 upvotes)
- "My terrifying and confusing drug experience." by PomegranateIcy6520 (9 upvotes)
- "How I lost my mind on methylphenidate " by WeakAd2476 (8 upvotes)
- "225ug + Cannabis, my First Time Tripping" by sharbowarbo (8 upvotes)
- "Fuck Around And Find Out Nothing, or how I realized recreational amphetamine use was pointless for me" by Godless_Phoenix (4 upvotes)
- "Mind Blowing DOM Trip Report 2,5-Dimethoxy-4-methylamphetamine" by Lurendrejeriii (4 upvotes)
- "There are 45 psychedelic and dissociative trip reports in the Drug Users Bible: Download a free copy from here. Whether psychedelics are used for recreation, you need to look after yourself. Stay safe." by DMTrott (3 upvotes)
- "The LSD Trip that made me Quit Cigarettes:" by Endless_Weapons (3 upvotes)
- "My first experience with drugs - snorting methylphenidate" by Enough_Fun9349 (2 upvotes)
- "Nutmeg + LSD + Cannabis + Ritalin + Alprazolam + Alcohol +N2O Combination!" by Endless_Weapons (1 upvotes)
- "340mg of Vyvanse / Trip report" by username_pickle (1 upvotes)
- "320mg vyvanse trip report" by username_pickle (1 upvotes)
- "My first time with DXM" by Toasterbath5 (1 upvotes)
- "Methylphenidate wonders - concerta - Experienced" by naixel4200 (0 upvotes)
- "9/22/2021 pyra (xan like) and mph (methylphenidate like)" by WhatAHenk (0 upvotes)
Legal status []
- Australia: Methylphenidate is a Schedule 8.
- Brazil: Methylphenidate is a A3.[4]
- Canada: Methylphenidate is a Schedule III.[5][6][7]
- Germany: Methylphenidate is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
- United Kingdom: Methylphenidate is a Class B under the "Misuse of Drugs Act 1971".
- New Zealand: Methylphenidate is a Class B2 -authority required.[8]
- United States: Methylphenidate is a Schedule II under the "Controlled Substances Act".[9]
- European Union: Methylphenidate is Prescription only.
- United Nations: Methylphenidate is a Schedule II psychotropic under the "Convention on Psychotropic Substances 1971".
- Other: Methylphenidate is a SE: Förteckning II MX: Controlled (estupefaciente).[10][11]
See also []
External links []
- Methylphenidate (Wikipedia)
- Methylphenidate (PubChem)
- Methylphenidate (Wikidata)
- Methylphenidate (DrugBank)
- Methylphenidate (ChEMBL)
- Methylphenidate (ChEBI)
- Methylphenidate (Common Chemistry)
- Methylphenidate (HMDB)
- Methylphenidate (KEGG)
- Methylphenidate (EPA DSSTox)
- Methylphenidate (Effect Index)
- Methylphenidate (UNII)
- Methylphenidate (SIDER)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4158, Methylphenidate. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4158
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Methylphenidate. UNII: 207ZZ9QZ49. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/207ZZ9QZ49
Stahl SM. Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. April 2024.
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Ritalin Product information. Health Canada. 25 April 2012. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=800
Controlled Drugs and Substances Act. Justice Laws Website. 31 March 2022. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html
Mental health. Health Canada. 9 May 2018. https://www.canada.ca/en/services/health/drug-health-products/drug-medical-device-highlights-2017/approved-drugs/mental-health.html
Ritalin® (IR and LA). Medsafe NZ. https://www.medsafe.govt.nz/profs/datasheet/r/RitalintabSRtabLAtab.pdf
Finlator J. Phenmetrazine and its salts, and Methylphenidate. Federal Register. 28 October 1971. https://archives.federalregister.gov/issue_slice/1971/10/28/20685-20687.pd#page=2f
Ritalin®, Tablett 10 mg. FASS. 10 September 2025. https://fass.se/health/product/20040607007433/fass-text
Ley General de Salud. Cámara de Diputados del H. Congreso de la Unión. 15 January 2026. https://www.diputados.gob.mx/LeyesBiblio/pdf/LGS.pdf
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | ok | 2026-11-20 10:23:35 |
| drugspro | ok | 2026-11-20 10:23:31 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 10:23:31 |
| gsrs | ok | 2026-11-20 10:23:32 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014566) | 2026-11-20 10:23:31 |
| kegg | ok | 2026-11-20 10:23:34 |
| pubchem | ok | 2026-11-20 10:23:30 |
| ok | 2026-11-20 10:23:31 | |
| sider | ok | 2026-11-20 10:23:31 |
| structure | ok | 2026-11-20 10:23:31 |
| wikipedia | ok | 2026-11-20 10:23:31 |